All In Biotech

Drug Trial Radar · NCT02634307

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jul 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,057

Actual

Start

Dec 10, 2015

Primary completion

Jun 1, 2021

Study completion Nov 11, 2021

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
Alkermes, Inc.
First posted
Dec 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The secondary objective of this study is to evaluate treatment effect over time in adult participants with RRMS treated with ALKS 8700.

Conditions

  • Multiple Sclerosis

Interventions

  • ALKS 8700Drug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From first dose to two weeks after last dose of study drug (Up to 98 weeks)
  2. Number of Participants With Potentially Clinically Significant Vital Sign AbnormalitiesTime frame: From first dose to two weeks after last dose of study drug (Up to 98 weeks)
  3. Number of Participants With Potentially Clinically Significant 12-Lead Electrocardiogram (ECG) AbnormalitiesTime frame: From first dose to two weeks after last dose of study drug (Up to 98 weeks)
  4. Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Score at Any Post-Baseline VisitTime frame: Up to 98 weeks
  5. Number of Participants With Potentially Clinically Significant Laboratory AbnormalitiesTime frame: From first dose to two weeks after last dose of study drug (Up to 98 weeks)

Locations

115 sites in 10 countries. Site status is shown where the registry gives one.

  • Alkermes Investigational Site

    Cullman, Alabama

  • Alkermes Investigational Site

    Phoenix, Arizona

  • Alkermes Investigational Site

    Phoenix, Arizona

  • Alkermes Investigational Site

    Phoenix, Arizona

  • Alkermes Investigational Site

    Tucson, Arizona

  • Alkermes Investigational Site

    Berkeley, California

  • Alkermes Investigational Site

    Loma Linda, California

  • Alkermes Investigational Site

    Long Beach, California

  • Alkermes Investigational Site

    San Diego, California

  • Alkermes Investigational Site

    Basalt, Colorado

  • Alkermes Investigational Site

    Centennial, Colorado

  • Alkermes Investigational Site

    Denver, Colorado

  • Alkermes Investigational Site

    Middlebury, Connecticut

  • Alkermes Investigational Site

    Stamford, Connecticut

  • Alkermes Investigational Site

    Washington D.C., District of Columbia

  • Alkermes Investigational Site

    Atlantis, Florida

  • Alkermes Investigational Site

    Bradenton, Florida

  • Alkermes Investigational Site

    Jacksonville, Florida

  • Alkermes Investigational Site

    Maitland, Florida

  • Alkermes Investigational Site

    Naples, Florida

  • Alkermes Investigational Site

    Ormond Beach, Florida

  • Alkermes Investigational Site

    Sarasota, Florida

  • Alkermes Investigational Site

    Tampa, Florida

  • Alkermes Investigational Site

    Vero Beach, Florida

  • Alkermes Investigational Site

    Atlanta, Georgia

  • Alkermes Investigational Site

    Atlanta, Georgia

  • Alkermes Investigational Site

    Atlanta, Georgia

  • Alkermes Investigational Site

    Columbus, Georgia

  • Alkermes Investigational Site

    Evanston, Illinois

  • Alkermes Investigational Site

    Indianapolis, Indiana

  • Alkermes Investigational Site

    Indianapolis, Indiana

  • Alkermes Investigational Site

    Des Moines, Iowa

  • Alkermes Investigational Site

    Overland Park, Kansas

  • Alkermes Investigational Site

    Lexington, Kentucky

  • Alkermes Investigational Site

    Alexandria, Louisiana

  • Alkermes Investigational Site

    Baton Rouge, Louisiana

  • Alkermes Investigational Site

    Detroit, Michigan

  • Alkermes Investigational Site

    Traverse City, Michigan

  • Alkermes Investigational Site

    Golden Valley, Minnesota

  • Alkermes Investigational Site

    St Louis, Missouri

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.